ArticleKidney international2009
Tissue proteomics: a new investigative tool for renal biopsy analysis.
Article in Kidney international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- GlomSAM: Hybrid customized SAM for multi-glomerular detection and segmentation in immunofluorescence images.PloS one · 2025Article
- Randall-Type Monoclonal IgE Kappa Light-Heavy Chain Deposition Disease.Kidney international reports · 2023Article
- Cryo-Gel embedding compound for renal biopsy biobanking.Scientific reports · 2019Article
- Proteomic analysis of formalin-fixed paraffin-embedded glomeruli suggests depletion of glomerular filtration barrier proteins in two-kidney, one-clip hypertensive rats.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2014Article
- Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis.Clinical journal of the American Society of Nephrology : CJASN · 2010Article
- Screening for chronic kidney disease in HIV-infected patients.Advances in chronic kidney disease · 2010Review
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
Abstract
Renal biopsy is viewed as the gold standard for diagnosis and management of many kidney diseases, especially glomerulopathies. However, the histopathological descriptions currently used in clinical practice often are neither diagnostic nor prognostic. The paper by Sethi et al. highlights the availability of a newer investigative tool that can be used to better define pathogenesis and, perhaps more important, to discover robust biomarkers of kidney disease cause and outcome.
Indexed as
Identifiers
19367311What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.